Search results
Results from the WOW.Com Content Network
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC ...
A clinical TTFields device is manufactured by Novocure under the trade name Optune (formerly NovoTTF-100A), and is approved in the United States, Japan, Israel and multiple countries in Europe for the treatment of recurrent glioblastoma. These devices generate electromagnetic waves between 100 and 300 kHz. The devices can be used in conjunction ...
Also Read: FDA Approves NovoCure’s Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients. In the intent-to-treat population, ...
Novocure (NASDAQ: NVCR) and its international partner Zai Lab (NASDAQ: ZLAB) announced successful top-line results from the Panova-3 study on Dec. 2, 2024. ... Another FDA approval to treat ...
NovoCure (NASDAQ: NVCR) Q3 2024 Earnings Call Oct 30, 2024, 8:00 a.m. ET. Contents: ... the FDA approved our PMA for Optune Lua to treat post-platinum metastatic non-small cell lung cancer ...
The FDA approval was based on a clinical trial of 372 participants with relapsed mycosis fungoides or Sézary syndrome who received either mogamulizumab or a type of chemotherapy called vorinostat. The FDA granted the application for mogamulizumab priority review, breakthrough therapy , and orphan drug designations.
The FDA approved tafasitamab based primarily on evidence from one clinical trial (NCT02399085) of 81 participants 42 to 86 years old. [7] Participants in the trial had lymphoma that relapsed or did not improve after prior treatments. [7] The trial was conducted at 35 sites in the United States and Europe. [7]
The device is approved for use in a type of cancer that starts in the brain and spinal cord and the cancer of a thin tissue called mesothelium. The device, branded as Optune Gio and Optune Lua ...